Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Operations: 2020-2025

Historic Cash from Operations for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$46.5 million.

  • 4D Molecular Therapeutics' Cash from Operations fell 58.20% to -$46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$183.5 million, marking a year-over-year decrease of 61.85%. This contributed to the annual value of -$134.6 million for FY2024, which is 77.57% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Cash from Operations of -$46.5 million as of Q3 2025, which was down 7.20% from -$43.4 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Cash from Operations peaked at -$1.2 million during Q3 2023, and registered a low of -$47.8 million during Q1 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' median Cash from Operations value was -$29.4 million (recorded in 2024), while the average stood at -$31.6 million.
  • In the last 5 years, 4D Molecular Therapeutics' Cash from Operations surged by 94.43% in 2023 and then tumbled by 2,409.91% in 2024.
  • 4D Molecular Therapeutics' Cash from Operations (Quarterly) stood at -$21.8 million in 2021, then dropped by 1.73% to -$22.2 million in 2022, then dropped by 10.97% to -$24.6 million in 2023, then plummeted by 86.06% to -$45.9 million in 2024, then tumbled by 58.20% to -$46.5 million in 2025.
  • Its Cash from Operations was -$46.5 million in Q3 2025, compared to -$43.4 million in Q2 2025 and -$47.8 million in Q1 2025.